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Understanding the mechanisms that control processing of the amyloid precursor protein (APP) to produce
amyloid-b (Ab) peptide represents a key area of Alzheimer’s disease research. Here, we show that siRNA-
mediated loss of calsyntenin-1 in cultured neurons alters APP processing to increase production of Ab.
We also show that calsyntenin-1 is reduced in Alzheimer’s disease brains and that the extent of this reduction
correlates with increased Ab levels. Calsyntenin-1 is a ligand for kinesin-1 light chains and APP is trans-
ported through axons on kinesin-1 molecular motors. Defects in axonal transport are an early pathological
feature in Alzheimer’s disease and defective APP transport is known to increase Ab production. We show
that calsyntenin-1 and APP are co-transported through axons and that siRNA-induced loss of calsyntenin-
1 markedly disrupts axonal transport of APP. Thus, perturbation to axonal transport of APP on calsynte-
nin-1 containing carriers induces alterations to APP processing that increase production of Ab.T o g e t h e r ,
our ﬁndings suggest that disruption of calsyntenin-1-associated axonal transport of APP is a pathogenic
mechanism in Alzheimer’s disease.
INTRODUCTION
Deposition of amyloid-b (Ab) within amyloid plaques is a
hallmark pathology of Alzheimer’s disease. Ab is an approxi-
mate 40 amino acid peptide that is derived by proteolytic
cleavage from amyloid precursor protein (APP). Processing
of APP to produce Ab involves cleavage by b-site APP cleav-
ing enzyme-1 (BACE1) and g-secretase that process APP at
the N- and C-termini, respectively, of the Ab sequence. In
addition, APP can be cleaved by a- and g-secretases and
this precludes Ab production since a-secretase cleaves APP
within the Ab sequence (1).
A large body of evidence suggests that altered production of
Ab is a major pathogenic event in Alzheimer’s disease (2).
Indeed, some familial forms of Alzheimer’s disease are
caused by mutations in the APP gene and several of these
mutations alter processing of APP and production of Ab (2).
Understanding the molecular mechanisms that control APP
processing thus represents a key area of Alzheimer’s disease
research. Alterations to APP trafﬁcking are acknowledged to
be one mechanism for modulating APP processing and Ab
production (3).
Neurons are especially dependent upon correct protein and
organelle trafﬁcking since they are polarized with axons and
dendrites, and also because transport through axons can
involve cargo movement over exceptionally long distances.
Moreover, a large body of evidence now implicates defective
axonal transport in Alzheimer’s disease (reviewed in 4–6).
Within neurons, APP is synthesized in cell bodies and then
undergoes anterograde axonal transport on kinesin-1 molecu-
lar motors (7,8). Most functional kinesin-1 comprises a hetero-
tetramer of two kinesin-1 motor proteins and two kinesin-1
†These authors contributed equally to this work.
∗To whom correspondence should be addressed at: Department of Neuroscience P037, Institute of Psychiatry, De Crespigny Park, Denmark Hill.
London SE5 8AF, UK. Tel: +44 2078480393; Email: chris.miller@kcl.ac.uk
# The Author 2012. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop-
erly cited.
Human Molecular Genetics, 2012, Vol. 21, No. 13 2845–2854
doi:10.1093/hmg/dds109
Advance Access published on March 20, 2012light chains (KLCs). Kinesin-1 contains ATPase activity and
uses the chemical energy of ATP to drive conformational
changes that generate motile force; in contrast, the KLCs are
mainly involved in binding of cargoes (9).
The precise mechanisms by which APP attaches to and is
transported by kinesin-1 are not properly understood (reviewed
in 10). However, there is evidence that one route may
involve calsyntenin-1 (also known as alcadein-a)( 11,12).
Calsyntenin-1 is a neuronally enriched type-1 membrane-
spanningprotein thatbinds directlytoKLCs via itsintracellular
C-terminal domain (13–16). As such, calsyntenin-1 acts as a
ligand to mediate transport of a subset of vesicles through
axons on kinesin-1 motors. A proportion of APP and
calsyntenin-1 co-localize in cells and tissues, and proteomic
studies have shown that some calsyntenin-1 containing vesicles
also contain APP (11,12). However, such studies are correl-
ational and do not formally demonstrate that calsyntenin-1 is
required for movement of APP in neurons. Indeed, other
studies suggest that calsyntenin-1 does not normally mediate
axonal transport of APP (14). Likewise, the effect of
calsyntenin-1 on APP processing and Ab production is
unclear. Some studies indicate that the loss of calsyntenin-1
promotes APP processing, whereas others indicate that over-
expression of calsyntenin-1 increases Ab production (12,14).
Notably, the effect of loss of calsyntenin-1 on Ab production
in neurons has not been reported.
To obtain formal evidence on the role of calsyntenin-1 in
transport and processing of APP, we monitored how siRNA
loss of calsyntenin-1 inﬂuenced APP axonal transport and pro-
duction of endogenous Ab in living neurons. Here, we show
that APP and calsyntenin-1 are co-transported through
axons, that the loss of calsyntenin-1 disrupts axonal transport
of APP and that calsyntenin-1 loss also leads to altered APP
processing and increased production of Ab. Finally, we dem-
onstrate that calsyntenin-1 expression is reduced and negative-
ly correlates with Ab burden in Alzheimer’s disease brains.
Thus, altered axonal transport of APP on calsyntenin-1 carriers
may be mechanistic in Alzheimer’s disease.
RESULTS
siRNA-mediated loss of calsyntenin-1 increases
Ab production in neurons
We ﬁrst tested the role of calsyntenin-1 on production of Ab.
To do so, we downregulated calsyntenin-1 expression in rat
cortical neurons using siRNAs and monitored production of
endogenous Ab(1–40) and Ab(1–42) species using ELISAs.
Two different siRNAs and a Smartpool mix of four siRNAs
all reduced calsyntenin-1 expression to lower than 5% of
that seen in control cells (Fig. 1A). Ab ELISAs revealed
that this reduction in calsyntenin-1 expression led to a signiﬁ-
cant approximate 1.65-fold increase in secretion of both
Ab(1–40) and Ab(1–42) (Fig. 1B). Since all three siRNAs
produced highly similar effects on calsyntenin-1 expression
and Ab production, the Smartpool mix was used in all later
experiments.
siRNA-mediated loss of calsyntenin-1 increases APP
processing at the BACE1 site but does not alter the levels
of BACE1, ADAM10, presenilin-1, nicastrin, full-length
APP or phosphorylation of APP on threonine-668
To gain insight into the mechanisms by which the loss of
calsyntenin-1 increased production of Ab, we ﬁrst monitored
APP levels and APP processing at the a-secretase and BACE1
sites in neurons treated with control or calsyntenin-1 siRNAs
by immunoblotting. Processing of APP by a-secretase and
BACE1 generates N-terminal secreted APP fragments (sAPPa
and sAPPb) and the corresponding membrane-associated APP
C-terminal domains. These APP C-terminal domains corres-
pond to the two fragments produced by BACE1 processing
(99 and 89 amino acids; APP-C99 and APP-C89) and the frag-
ment produced by a-secretase processing (83 amino acids;
APP-C83) (1). While the C-terminal APP fragments can
be resolved on SDS–PAGE, analysis is complicated since
in neurons, a proportion of APP is phosphorylated on
threonine-668 (APP-thr668) by c-Jun N-terminal kinase-3
which alters the migration pattern of the different processed
species so that some co-migrate (17,18). However, treatment
of samples with l-protein phosphatase prior to analyses
facilitates interpretation of the band pattern (18).
Loss of calsyntenin-1 did not alter the total levels of full-
length APP (Fig. 2A). However, analyses of APP C-terminal
processed fragments (APP-CTFs) in cell lysate samples
showed that the loss of calsyntenin-1 decreased the level of
APP-C83 and increased the levels of both APP-C89 and
Figure 1. siRNA knockdown of calsyntenin-1 increases production of Ab.( A)
Knockdown of calsyntenin-1 in rat cortical neurons. Neurons were treated
with control siRNA (Ctrl) or with two different calsyntenin-1 siRNAs
(Cstn#1; Cstn#2) or with a pool of four different calsyntenin-1 siRNAs
(Cstn-pl). Samples were then probed on immunoblots for calsyntenin-1
(Cstn) or actin as a loading control. Molecular mass markers are shown. (B)
ELISA assays for Ab(1–40) and Ab(1–42) in conditioned media from rat cor-
tical neurons treated with control siRNA (Ctrl) or with two different
calsyntenin-1 siRNAs (Cstn#1; Cstn#2) or with a pool of four different
calsyntenin-1 siRNAs (Cstn-pl). Treatment with calsyntenin-1 siRNAs in-
crease the amounts of both Ab(1–40) and Ab(1–42) in conditioned media.
Statistical signiﬁcance was determined by one-way ANOVA followed by
the Bonferroni post hoc test. n ¼ 6; error bars are SEM; ∗∗P , 0.01.
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observed in the l-protein phosphatase-treated samples
(Fig. 2A). To complement these analyses, we also monitored
APPprocessingbyimmunoblottingforAPP-secretedfragments
in conditioned media. Probing with antibody 22C11 (that
detects total sAPP) and antibodies that speciﬁcally detect
sAPPa and sAPPb revealed that while the loss of calsyntenin-1
did not alter the total sAPP levels, it induced a decrease in
sAPPa and a corresponding increase insAPPb levels (Fig. 2B).
APP-thr668 phosphorylation has been linked to axonal trans-
port of APP and Ab production (19–21). We therefore moni-
tored the effect of calsyntenin-1 knockdown on APP-thr668
phosphorylation. Loss of calsyntenin-1 did not alter the levels
of phosphorylated full-length APP (Fig. 2A). Moreover,
changes in phosphorylation of APP-C99, APP-C89 and
APP-C83 were in line with the relative changes in the total
amounts of these processed fragments (Fig. 2A).
We also monitored whether the loss of calsyntenin-1 altered
the levels of BACE1, the a-secretase ADAM10, the
g-secretase components presenilin-1 and nicastrin (1) and
X11b by immunoblotting. X11b (also known as X11-like or
munc-18 interacting protein-2) binds to both APP and
calsyntenin-1 (22,23). Knockdown of calsyntenin-1 did not
change the levels of any of these secretases or X11b
(Fig. 2C). Thus, the increased production of Ab associated
with the loss of calsyntenin-1 is accompanied by a decrease
in processing of APP at the a-secretase site and a correspond-
ing increase in processing at the BACE1 sites. However, these
changes do not involve alterations to the levels of full-length
APP, APP-thr668 phosphorylation, APP secretases or X11b.
A signiﬁcant proportion of APP and calsyntenin-1
co-localize in axons and APP-mCherry and enhanced
green ﬂuorescent protein-calsyntenin-1 are co-transported
through living axons
Since calsyntenin-1 functions as a ligand for kinesin-1 and
APP is transported on kinesin-1 motors, the effect of
calsyntenin-1 loss on APP processing and Ab production
may be due to changes in axonal transport of APP. Indeed, dis-
ruption of kinesin-1-mediated APP axonal transport alters APP
processing to increase Ab production (8). To begin to test this
possibility, we ﬁrst monitored co-localization of APP and
calsyntenin-1 in neurons. Both APP and calsyntenin-1 are
enriched in the Golgi and calsyntenin-1 has been shown to
mediate kinesin-1 transport of cargoes on post-Golgi carriers
(12,15). In line with these ﬁndings, a proportion of
calsyntenin-1 co-localized with the trans-Golgi network
(TGN) marker TGN-38 and proportions of both calsyntenin-1
Figure 2. siRNA knockdown of calsyntenin-1 alters APP processing in rat cor-
tical neurons without affecting expression of APP or APP secretase proteins.
(A). Neurons were treated with control (Ctrl) or calsyntenin-1 (Cstn)
siRNAs (pooled mix of four different siRNAs) and samples then probed on
immunoblots for full-length APP (APP), full-length APP phosphorylated on
threonine-668 (APP-p), APP C-terminal processed fragments (APP-C), APP
C-terminal processed fragments phosphorylated on threonine-668 (APP-Cp)
or APP C-terminal processed fragments following treatment with l-protein
phosphatase (APP-C lpp). Immunoblots showing APP C-terminal processed
fragments are marked to indicate APP species generated following cleavage
by BACE1 (C99 and C89) or a-secretase (C83), and their phosphorylated var-
iants (pC99, pC89, pC83). Bar graphs show relative levels of APP C-terminal
fragments (APP-C83; APP-C89 and APP-C99) in the different samples fol-
lowing treatment with l-protein phosphatase. Statistical signiﬁcance was
determined by Student’s t-test. n ¼ 5; error bars are SEM. ∗P , 0.05;
∗∗P , 0.01. No signiﬁcant changes in the levels of full-length APP or full-
length APP phosphorylated on threonine-668 were detected in the same
samples. (B) sAPP fragments in conditioned media of rat cortical neurons
treated with control (Ctrl) or calsyntenin-1 (Cstn) siRNAs. Samples were
probed on immunoblots for total sAPP (sAPP), sAPPa and sAPPb. Bar
graph shows relative levels of sAPPa and sAPPb in the different samples;
total sAPP levels were unchanged. Statistical signiﬁcance was determined
by Student’s t-test. n ¼ 4; error bars are SEM. ∗P , 0.05; ∗∗P , 0.01. (C)
siRNA knockdown of calsyntenin-1 does not affect expression of BACE1,
a-o rg-secretase proteins or X11b. Neurons were treated with control (Ctrl)
or calsyntenin-1 siRNAs (Cstn) and samples (n ¼ 4) then probed on immuno-
blots for BACE1, ADAM10, N- and C-terminal presenilin-1 (PS1) fragments,
nicastrin and X11b as indicated. Molecular mass markers are shown.
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APP and calsyntenin-1 also co-localized in vesicular
structures in axons (Fig. 3B). Quantiﬁcation of this axonal
co-localization revealed that 41% of APP vesicles co-localized
with calsyntenin-1. These ﬁndings are in broad agreement
with previous studies which showed that in sciatic nerve and
in axons of cultured hippocampal neurons,  30–45% of
APP and calsyntenin-1 co-localize (11,14). We also monitored
the axonal distributions of transfected enhanced green ﬂuores-
cent protein (EGFP) -calsyntenin-1 and APP-mCherry in
neurons. High levels of co-localization of these transfected
proteins were detected in axons (Fig. 3C).
The co-localization of APP and calsyntenin-1 in axons
suggest that they are co-transported. We therefore monitored
axonal transport of APP-mCherry and EGFP-calsyntenin-1
by dual imaging time-lapse microscopy in co-transfected
living rat cortical neurons. In line with our previous work
(15,24), we chose cells expressing low levels of transfected
proteins (as judged by the ﬂuorescent protein signal) for ana-
lyses so as to avoid any possible artefacts produced by high
levels of expression. Co-ordinate movement of APP-mCherry
and EGFP-calsyntenin-1 in both anterograde and retrograde
directions was observed through axons (Fig. 4A). Movement
was predominantly anterograde and mean speeds were
1.6 mm/s (anterograde) and 1.1 mm/s (retrograde). These
velocities and the bias towards anterograde movement
are similar to those described previously for calsyntenin-1
(13–15). APP-YFP/EGFP also moves in a predominantly an-
terograde direction with reported speeds of 0.8–9 mm/s which
may depend to some extent upon the cell type utilized
(7,14,25–27). Notably,  65% of APP-EGFP is transported
at speed of 1–2 mm/s in mouse cortical neurons which are
similar to the speeds reported here in rat cortical neurons (26).
siRNA loss of calsyntenin-1 decreases axonal
transport of APP
The above co-localization and live imaging studies suggest
that a signiﬁcant proportion of APP is co-transported with
calsyntenin-1 through axons. To test further this possibility,
we quantiﬁed APP-EGFP axonal transport using time-lapse
microscopy in transfected living rat cortical neurons following
siRNA knockdown of calsyntenin-1. APP-EGFP movement
was again predominantly anterograde in these neurons.
However, analyses of the ﬂux rates for APP-EGFP transport
revealed that the loss of calsyntenin-1 markedly reduced the
numbers of APP-EGFP moving cargoes (Fig. 4B–D). This
reduction was seen in both anterograde (64.3% reduction)
and retrograde (46.6% reduction) directions (Fig. 4D). Thus,
APP and calsyntenin-1 co-localize in axons, APP-mCherry
and EGFP-calsyntenin-1 are co-transported through axons,
and the loss of calsyntenin-1 markedly disrupts axonal
transport of APP.
siRNA loss of calsyntenin-1 increases APP levels
in the TGN
Calsyntenin-1 is enriched in the Golgi and mediates trans-
Golgi exit of APP (12). The reduced axonal transport of
APP-EGFP seen in calsyntenin-1 knockdown neurons sug-
gests that APP may be retained in the cell body and accumu-
late in the TGN. To test this possibility, we quantiﬁed the APP
ﬂuorescent signals in the TGN in control and calsyntenin-1
siRNA-treated neurons. Loss of calsyntenin-1 induced a sig-
niﬁcant 54.7% increase in APP signals in the TGN (Fig. 5).
Calsyntenin-1 expression is reduced in Alzheimer’s disease
brains and the extent of this reduction correlates inversely
with Ab levels
The above studies, which show that the loss of calsyntenin-1
increases Ab production and that this is associated with a dis-
ruption to axonal transport of APP, suggest that defects in
calsyntenin-1 metabolism may be mechanistic in Alzheimer’s
disease. To begin to test this possibility, we monitored
calsyntenin-1 expression in Alzheimer’s disease brains. Im-
munoblotting of cortical samples from control and Braak
stage V–VI Alzheimer’s disease brains revealed that com-
pared with controls, calsyntenin-1 expression was signiﬁcantly
reduced in Alzheimer’s disease brains (73.5 + 6.72% of
control) (Fig. 6A). There was no signiﬁcant correlation
between calsyntenin-1 levels and post-mortem delay.
Figure 3. Calsyntenin-1 is present in the TGN and APP and calsyntenin-1
co-localize in cell bodies and in axons of cultured rat cortical neurons. (A and
B)Neuronswereco-stainedforcalsyntenin-1andeitherTGN-38orAPPasindi-
cated. (A) Confocal slices through cell bodies with merge (calsyntenin-1 and
TGN-38) or co-localized pixels (calsyntenin-1 and APP). (B) Endogenous
calsyntenin-1 and APP in axons with co-localized puncta. (C)
EGFP-calsyntenin-1 and APP-mCherry in axons with co-localized puncta.
Scale bars are 10 mm (A) and 5 mm (B and C).
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Ab burden in these samples. Total Ab(1–40) and Ab(1–42)
were quantiﬁed by ELISAs and correlated with calsyntenin-1
protein levels. Signiﬁcant negative correlations were
observed between both Ab(1–40) (r
2 ¼ 20.396) and
Ab(1–42) (r
2 ¼ 20.441), and calsyntenin-1 levels (Fig. 6B).
DISCUSSION
Here, we show that the loss of calsyntenin-1 increases produc-
tion of endogenous Ab(1–40) and Ab(1–42) in rat neurons.
Wealsoshowthatcalsyntenin-1levelsarereducedsigniﬁcantly
in Alzheimer’s disease brains and that the extent of this reduc-
tion correlates signiﬁcantly with increased Ab levels. Loss of
calsyntenin-1intheculturedneuronswasassociatedwithaltera-
tions to APP processing involving increased cleavage at the
BACE1 sites and decreased cleavage at the a-secretase site.
APP is synthesized in the endoplasmic reticulum (ER) and
then trafﬁcked through the Golgi to the cell surface. Here, it
can be re-internalized to endocytic and recycling compart-
ments and trafﬁcked back to the cell surface or degraded in
the lysosome (3). Calsyntenin-1 is enriched in the TGN and
recent evidence suggests that it mediates transport of a
subset of cargoes on post-Golgi carriers via kinesin-1
(11,12). Our ﬁndings that siRNA loss of calsyntenin-1
reduces axonal transport of APP and increases APP levels in
the TGN are thus consistent with a role for calsyntenin-1 in
mediating transport of APP on post-Golgi carriers.
The precise intracellular location(s) where APP is processed
to produce Ab in neurons are not clear. BACE1 localizes
mainly to the TGN and endosomes, whereas g-secretase com-
ponents are found in multiple locations, including ER, Golgi,
endosomes and the cell surface (3,28). Thus, some studies
suggest that Ab is produced in endosomes (29–33), whereas
others suggest that the TGN is a primary site for Ab produc-
tion (34–39). There is also evidence that Ab is produced in
other locations, including autophagosomes (40). Whatever
the scenario, disrupting anterograde transport of APP may
well promote amyloidogenic processing by targeting APP to
sites of cleavage by BACE1 and/or g-secretase. In particular,
our ﬁnding that siRNA loss of calsyntenin-1 increases APP
levels in the TGN, a favoured site for APP processing by
BACE1 (see above) may explain the increased cleavage of
APP at the BACE1 sites that we detect in the calsyntenin-1
knockdown neurons.
Despite highly efﬁcient siRNA knockdown of
calsyntenin-1, its loss reduced but did not abolish anterograde
axonal transport of APP. Other mechanisms for transport of
APP by kinesin-1 have been described, including direct attach-
ment of APP to KLCs, or indirect attachment to KLCs via
adaptor proteins such as JIPs (C-Jun N-terminal kinase inter-
acting proteins) and PAT1 which bind to both KLC and
APP (14,19,41–43). The GTPase Rab3A has also been impli-
cated in APP transport (26). Transport involving these other
mechanisms may account for the remaining APP movement
seen in the calsyntenin-1 knockdown neurons. It is also
possible that the co-ordinate transport of APP-mCherry and
EGFP-calsyntenin-1 seen in our dual imaging studies overes-
timates the proportion of APP that is co-transported with
calsyntenin-1 (e.g. overexpression of calsyntenin-1 in these
experiments may recruit APP from JIP1/PAT1 carriers).
Figure 4. EGFP-calsyntenin-1 and APP-mCherry are co-transported through axons of rat cortical neurons and siRNA loss of calsyntenin-1 disrupts axonal trans-
port of APP-EGFP. (A) Kymograph showing co-transport of EGFP-calsyntenin-1 (Cstn) and APP-mCherry (APP). Merge and co-transported (Co-tr)
EGFP-calsyntenin-1/APP-mCherry particles are shown. (B and C) Representative kymographs showing axonal transport of APP-EGFP in control (B) and
calsyntenin-1 (C) siRNA-treated neurons. (D) Flux rates for APP-EGFP vesicle movement in control and calsyntenin-1 siRNA-treated neurons. Loss of
calsyntenin-1 disrupts APP-EGFP transport in both anterograde and retrograde directions. Statistical signiﬁcance was determined by Student’s t-test. n ¼ 33
control and 33 calsyntenin-1 siRNA-treated cells; error bars are SEM; ∗P , 0.05; ∗∗∗P , 0.001.
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calsyntenin-1 markedly inhibits anterograde movement of
APP strongly suggests that a signiﬁcant proportion of APP is
transported on calsyntenin-1 carriers. Indeed, using alternative
approaches that do not directly assay movement of APP
through axons, others have also concluded that an important
route for axonal transport of APP by kinesin-1 may involve
calsyntenin-1 (11,12).
Our ﬁndings that the loss of calsyntenin-1 disrupts axonal
transport of APP and increases production of Ab focus atten-
tion on the mechanism that controls APP transport on
calsyntenin-1 carriers. In particular, the mechanisms that
control loading of APP onto calsyntenin-1 containing vesicles
and binding of calsyntenin-1 to KLCs represent key regulatory
points that could inﬂuence APP trafﬁcking.
Although the route(s) by which APP is loaded onto
calsyntenin-1-containing vesicles are not clear, both APP
and calsyntenin-1 bind to X11b (22,23,44). X11b is a neuron-
al adaptor protein that is enriched in the Golgi and which reg-
ulates APP processing and Ab production (45–50). There is
evidence that X11b functions as a vesicle coat protein; coat
proteins function in the selection of cargo for inclusion into
particular vesicle sub-types (51). Interestingly, phosphoryl-
ation of KLC1 on serine-460 has recently been shown to se-
lectively regulate binding of calsyntenin-1 but not several
other ligands to kinesin-1 motors (15). Thus, via its binding
to both APP and calsyntenin-1, X11b may function to load
APP onto calsyntenin-1-containing vesicles for post-Golgi
transport on kinesin-1 motors, and phosphorylation of KLCs
may regulate attachment of calsyntenin-1 with associated
APP to kinesin-1. Disruption to loading of APP onto
calsyntenin-1 vesicles or transport of APP by kinesin-1 on
calsyntenin-1 containing vesicles are thus likely to promote
amyloidogenic processing of APP. Moreover, the negative
correlation we detect between calsyntenin-1 and Ab levels
in Alzheimer’s disease brains suggest that the loss of
calsyntenin-1 is mechanistic in the disease process.
MATERIALS AND METHODS
Plasmids and siRNAs
EGFP-calsyntenin-1 and APP-EGFP were as described previ-
ously (13,52). APP-mCherry was generated by replacement
with mCherry sequences in APP-EGFP. Calysntenin-1 and
negative control siRNAs were from Dharmacon (Accell
range). Calsyntenin-1 siRNAs were #1 5′-GCAAAGAGC
AUCAGUAUAA-3′,# 25 ′-CCCUUAAGAUGUGUAUAU
U-3′,# 35 ′-CCAUCACGCUUGCAGUUUU-3′ and #4
5′-GUGUCAGCUUCCUGGUUUU-3′. Negative control
siRNA (catalogue number D-001910-03) has been designed,
modiﬁed and microarray-conﬁrmed by Dharmacon to have
minimal targeting of genes in rat cells (see http://www.dha
rmacon.com/).
Figure 6. Calsyntenin-1 is reduced in Alzheimer’s disease brains and the
extent of this reduction correlates with Ab levels. (A) Immunoblots of repre-
sentative samples from control (Ctrl) and Alzheimer’s disease (AD) cortex.
Samples were probed for calsyntenin-1 (Cstn) and NSE. Bar graph shows rela-
tive levels of calsyntenin-1 in the two sample sets following normalization to
NSE signals in each sample. Statistical signiﬁcance was determined by Stu-
dent’s t-test. n ¼ 19 control (Ctrl) and n ¼ 16 Alzheimer’s disease samples;
error bars are SEM. ∗∗P , 0.01. (B) Correlation between cortical
calsyntenin-1 amounts and Ab burden in post-mortem brains. Ab levels in
human tissues were correlated with calsyntenin-1 signals by generating correl-
ation coefﬁcients and signiﬁcance established by non-parametric, two-tailed,
Spearman Rho tests. Graphs show Ab(1–40) and Ab(1–42) levels (ng/g
brain tissue) plotted against calsyntenin-1 signals (arbitrary units) obtained
from immunoblots. Signiﬁcant negative correlations were observed between
both Ab(1–40) (r
2 ¼ 20.396; P , 0.05) and Ab(1–42) (r
2 ¼ 20.441; P ,
0.01) and calsyntenin-1 levels (n ¼ 19 control; n ¼ 16 Alzheimer’s disease
samples).
Figure 5. siRNA loss of calsyntenin-1 increases APP levels in the TGN.
Neurons were treated with control (Ctrl) or calsyntenin-1 (Cstn) siRNAs
and immunostained for APP and TGN-38. Representative cells are shown
with merge. Scale bar is 10 mm. Bar chart shows relative APP ﬂuorescent
signals in the TGN. Statistical signiﬁcance was determined by Student’s
t-test. n ¼ 50 control and 54 calsyntenin-1 siRNA-treated cells; error bars
are SEM; ∗∗∗P , 0.001.
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Rabbit calsyntenin-1 and APP C-terminal antibodies were as
described previously (15,53). Anti-beta-Actin clone AC-15
and anti-Nicastrin rabbit polyclonal antibodies were from
Abcam (Cambridge, MA, USA); anti-ADAM10/Kuz and
anti-presenilin-1 N-terminus rabbit polyclonal antibodies
were from EMD Chemicals (Gibbstown, NJ, USA);
anti-presenilin-1 C-terminus clone PS1-loop, anti-APP
mouse clone 22C11 and anti-APP mouse clone 2.F2.19B4
were from Millipore Bioscience Research Reagents (Massa-
chusetts, MA, USA); anti-sAPPa clone 2B3 and anti-sAPPb
rabbit polyclonal antibodies were from IBL International
(Hamburg, Germany), anti-phospho-threonine-668 APP
rabbit polyclonal antibody was from Cell Signaling Technol-
ogy (Danvers, MA, USA); anti-BACE1 rabbit polyclonal anti-
body was from Sigma-Aldrich (St Louis, MO, USA);
anti-X11b (Mint 2) and TGN-38 mouse monoclonal
antibodies were from BD Biosciences (San Jose, CA, USA);
neuron-speciﬁc enolase (NSE) antibody was from Dako
(Cambridge UK).
Cell culture and transfection
Cortical neurons were obtained from embryonic day 18 rat
embryos and cultured in Neurobasal medium containing B27
supplement, 100 IU/ml penicillin, 100 mg/ml streptomycin
and 2 mML -glutamine (Invitrogen). For siRNA knockdown
studies, neurons at DIV4 were treated with 1 mM siRNAs
and analysed at DIV8. For transfection studies, neurons
cultured on poly-L-lysine-coated glass cover slips in 12-well
plates were transfected using Lipofectamine 2000 (Invitrogen)
(1 mg DNA and 0.5 ml Lipofectamine 2000) as described by
the manufacturer at DIV7 and analysed on DIV8.
Ab1-40 and Ab1-42 ELISAs
Rat/mouse and human Ab1-40 and Ab1-42 ELISAs were
obtained from Invitrogen. Samples were processed according
to the manufacturer’s instructions.
SDS–PAGE and immunoblotting
Cells were harvested for SDS–PAGE by washing with
phosphate-buffered saline pre-warmed at 378C and scraping
into SDS–PAGE sample buffer and immediately heating to
1008C. l-Phosphatase treatment was as described previously
(54). Samples were separated on either 8 or 10% (w/v) acryl-
amide gels or for analyses of APP C-terminal processed frag-
ments on 16% (w/v) acrylamide Tris-tricine gels as described
previously (55). Separated proteins were then transferred to
Protran nitrocellulose membranes or for Tris-tricine gels, to
0.2 mm Optitran nitrocellulose membranes (Sigma) using a
Transblot system (BioRad) and then processed for immuno-
blotting. Signals on immunoblots were quantiﬁed using
ImageJ (National Institutes of Health) after scanning with an
Epson Precision V700 Photo scanner essentially as described
by us in previous studies (15,56). To ensure the signals
obtained were within the linear range, the mean background-
corrected optical density (OD) of each signal was interpolated
for an OD calibration curve created using a calibrated OD step
tablet (Kodak). Only ﬁlm exposures that gave OD signals
within the linear range of the OD calibration curve were
used for the statistical analyses.
Frozen human brain tissue was prepared as a 20% hom-
ogenate in ice-cold lysis buffer containing 50 mM Tris–HCl
pH 7.4, 0.9% (w/v) NaCl, 0.1% (v/v) Triton X-100, 10 mM
sodium ﬂuoride, 1 mM sodium orthovanadate, 2 mM ethylene-
diamine tetraacetic acid, 1 mM phenylmethylsulfonyl ﬂuoride
and complete protease inhibitors (Roche). Following hom-
ogenization, samples were centrifuged at 25 000g (av) for
20 min at 48C and prepared for SDS–PAGE by addition of
sample buffer. Signals on immunoblots were simultaneously
visualized and the relative amounts quantiﬁed using an
Odyssey imaging system and associated software (Li-Cor
Biosciences, Cambridge, UK). Data were analysed using
Student’s t-test.
Immunoﬂuorescence and time-lapse microscopy
Neurons were prepared for immunostaining by ﬁxing in 4%
paraformaldehyde in phosphate-buffered saline (PBS) for
20 min, quenching with 0.05 M NH4Cl for 15 min, washing
in PBS and then permeabilizing with 0.2% Triton X-100 in
PBS for 5 min. Following blocking with 5% goat serum
(Sigma) in PBS for 30 min, the samples were probed with
primary antibodies diluted in blocking solution (PBS contain-
ing 5% goat serum). Primary antibodies were then detected
using goat anti-mouse and anti-rabbit Igs coupled to Alexa
Fluor 488 or 546 (Invitrogen). Confocal images were captured
using a Zeiss LSM510Meta confocal microscope equipped
with a ×100 Plan-Apochromat 1.4 N.A. objective (Carl
Zeiss Ltd, Welwyn Garden City, UK). Non-confocal images
were captured using a Leica DM5000B microscope with
×63 HCX PL Fluotar phase objective. Co-localization of
signals was performed using ImageJ 1.44p with the RG2B
co-localization plug-in to determine co-localized pixels. To
quantify APP signals in the TGN, TGNs were ﬁrst marked
by immunostaining with TGN-38. APP signals in the deli-
neated areas were then quantiﬁed by calculating the average
pixel ﬂuorescence intensity using ImageJ. These signals
were then normalized by subtracting the background ﬂuores-
cence signals in each cell which were obtained from measure-
ments in nuclei. Data were analysed using Student’s t-test.
Live microscopy of APP-EGFP, APP-mCherry and
EGFP-calsyntenin-1 was performed with an Axiovert S100
microscope (Zeiss) equipped with a Lambda LS Xenon-Arc
light source (Sutter Instrument Company, Novato, CA,
USA), GFP or GFP-mCherry ﬁlter set (Chroma Technology
Corp., Rockingham, VT, USA), ×100 Plan-Apochromat 1.4
N.A. objective (Zeiss), Lambda 10-3 ﬁlter wheel (Sutter In-
strument Co.) and a Photometrics Cascade-II 512B High
Speed EMCCD camera (Photometrics, Tuscon, AZ, USA).
Twenty-four hours post-transfection, the cells were transferred
to a Ludin imaging chamber (Life Imaging Systems, Basel,
Switzerland) mounted on the stage of the microscope.
Neurons were maintained in a HEPES-buffered extracellular
neuronal solution (composition in mM: NaCl, 140; KCl, 5;
NaHCO3, 5; MgCl2.6H2O, 1; CaCl2, 1.2; Na2HPO4, 1.2;
Glucose, 10; Hepes, 20; pH 7.4) at 378C using an objective
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Temperature Control System (Life Imaging Systems).
Vesicle movements were recorded for 5 min with a 1 s time-
lapse interval using MetaMorph software (Molecular
Devices). A movement was deﬁned as a displacement of a par-
ticle of at least 2 mm, without reversal of direction of more
than 2 mm or pausing for longer than 5 s. For dual imaging
of APP-mCherry and EGFP-calsyntenin-1 transport,
co-transfected neurons were imaged using a two-channel
simultaneous imaging system (Dual View, Photometrics)
and vesicle movements were recorded for 2 min with a 2 s
time-lapse interval using MetaMorph software (Molecular
Devices). Image analysis was performed with ImageJ. The
ﬂux rates for APP-EGFP transport in both anterograde and
retrograde directions were determined essentially as described
(8,27) by counting the numbers of APP-EGFP particles that
crossed a deﬁned line in mid axons per minute. Statistical
signiﬁcance was determined using Student’s t-test. Images
presented were constructed using Adobe CS5 and have been
smoothened in ImageJ.
Human tissues
The post-mortem human frontal cortex was obtained from
control and pathologically conﬁrmed cases of Alzheimer’s
disease (Braak Stage V–VI) (Table 1). All tissue collection
and processing were carried out under the regulations and
licensing of the Human Tissue Authority and in accordance
with the Human Tissue Act, 2004. Calsyntenin-1 signals
were normalized against NSE, as neuronal loss or astrogliosis
may bias the data toward downregulation of neuronal proteins.
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